News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Fosun Pharma (02696.HK) Receives Approval for Clinical Trial Application of Injection for Early-stage Breast Cancer
Fosun Pharma (02696.HK) announced that the National Medical Products Administration (NMPA) has approved the Phase 1 clinical trial application (INDs) for its independently develope...
Reset
Send
The window will close in 5 seconds
Fosun Pharma (02696.HK) Receives Approval for Clinical Trial Application of Injection for Early-stage Breast Cancer
Close
Recommend
3
Positive
0
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

Fosun Pharma (02696.HK)  +2.150 (+2.688%)    Short selling $5.80M; Ratio 11.100%   announced that the National Medical Products Administration (NMPA) has approved the Phase 1 clinical trial application (INDs) for its independently developed biosimilar injection HLX319 (subcutaneous injection) of pertuzumab-trastuzumab. The company plans to conduct related clinical trials in China once conditions are met.

HLX319 is an independently developed biosimilar injection of pertuzumab-trastuzumab (subcutaneous injection) by the company. It consists of the active ingredients trastuzumab, pertuzumab, and the excipient hyaluronidase (HLXTEHAase02, a novel recombinant human hyaluronidase independently developed by the company). It is intended for adjuvant/neoadjuvant treatment of early-stage breast cancer and treatment of metastatic breast cancer. (hc/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-10 12:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.